1-20 of 3873 Search Results for

treat lymphoma leukemia myeloma

Follow your search
Access your saved searches in your account

Would you like to receive an alert when new items match your search?
Close Modal
Sort by
Images
Up-regulation of proteasome pathway and the growth inhibitory effect of pro...
Published: 2010
Figure 5 Up-regulation of proteasome pathway and the growth inhibitory effect of proteasome inhibitors on T-ALL cells . (A) GSEA histograms for human T-ALL cells (cell lines or primary clinical samples) representing the “proteasome pathway.” The NES and the nominal P value are indicated. GSI-tr... More
Images
15d-PGJ 2   inhibits constitutive NF- κ B binding activity and induces apop...
Published: 2005
Figure 6. 15d-PGJ 2 inhibits constitutive NF- κ B binding activity and induces apoptosis in different types of B-cell malignancies. (A) Burkitt lymphoma HS-Sultan and BL-41 cells, multiple myeloma U266 and RPMI-8226 cells, and acute leukemia K562 cells (0.5 × 10 6 cell/mL) were treated with ... More
Images
A 73-year-old man with a 2-year history of bilateral lung transplantation p...
Published: 2021
A 73-year-old man with a 2-year history of bilateral lung transplantation presented with progressive fatigue, nausea, and night sweats over the past 2 months. Laboratory tests showed abnormal serum components: creatinine, 460.0 µmol/L; lactate dehydrogenase, 3073 U/L; immunoglobulin A (IgA) lambda p... More
Images
ActD treatment induces cell death in human  TP53  wt  B-cell <span class="search-highlight">lymphomas</span>.  (A...
Published: 2021
Figure 5. ActD treatment induces cell death in human TP53 wt B-cell lymphomas. (A) ActD IC 50 values of a data set with 740 tumor cell lines from the Genomics of Drug Sensitivity in Cancer (GDSC) database ranked by sensitivity to ActD (left) and box plot showing IC 50 values of hematologic ... More
Journal Articles
Journal: Blood
Blood (2016) 128 (22): 1989.
Published: 2016
... malignancies included: MM (n=1, 8%), diffuse large B-cell lymphoma (n=1, 8%), Waldenström's macroglobulinemia (n=1, 8%), CLL (n=2, 15%) and acute lymphoblastic leukemia (n=1, 8%). Four (31%) patients needed chemotherapy, with outcomes including: complete remission in one case (multiple myeloma), progression...
Journal Articles
Journal: Blood
Blood (2017) 130 (Suppl_1): 861.
Published: 2017
... distributions of <65, 65-74 and ≥ 75 years. The rates of enrollment for patients with chronic myeloid leukemia (CML), chronic lymphocytic leukemia (CLL), multiple myeloma (MM) and lymphomas (Hodgkin's and non-Hodgkin's lymphoma excluding CLL) were compared with the age distribution of incidence cases by site...
Journal Articles
Journal: Blood
Blood (2021) 138 (Supplement 1): 2277.
Published: 2021
... to red blood cells, non-ADCC direct tumor killing and elicits immunogenic cell death and DAMP induction, all in addition to single-agent phagocytosis. In vivo, AO-176 has exhibited broad anti-tumor activity in preclinical xenograft models of multiple myeloma (MM), acute myeloid leukemia, T cell acute...
Journal Articles
Journal: Blood
Blood (2016) 128 (22): 4443.
Published: 2016
...). The risk was higher for developing multiple myeloma (SIR 30.8 25-38 AER 67/10,000), leukemia (SIR 3.4, 95% CI; 2-5.2 AER 10/10,000) and non-Hodgkin's lymphoma (NHL) (SIR 3.2, 95 % CI 2.1-4.7 AER 13.4/10,000) in "two-month" survivors of plasmacytoma as compared to general population. The risk of developing...
Journal Articles
Journal: Blood
Blood (2019) 134 (Supplement_1): 1291.
Published: 2019
... "DNA-barcoded" cell lines (PRISM system) from hematologic malignancies, including multiple myeloma (MM), leukemias and lymphomas, which were treated for 48hr with M3258. MM cell lines (9/16) were strongly represented among the sensitive lines which displayed <50% relative cell viability (compared...
Journal Articles
Journal: Blood
Blood (2020) 136 (Supplement 1): 18.
Published: 2020
... was administered were assessed through likelihood ratio tests of a generalized linear mixed model. Results Overall, 3,308 patients were treated in 161 trials. Median age of the patients was 61 (range: 0-96) and 61% were male. Acute myeloid leukemia/myelodysplastic syndrome (AML/MDS) was the most common enrolled...
Journal Articles
Journal: Blood
Blood (2019) 134 (Supplement_1): 1844.
Published: 2019
... hematologic cancers in vitro and in vivo. As a single agent, AO-176 not only promotes phagocytosis (15-45%, EC 50 = 0.33-4.1 µg/ml) of hematologic tumor cell lines (acute myeloid leukemia, non-Hodgkin's lymphoma, multiple myeloma, and T cell leukemia) but also directly targets and kills tumor cells (18-46...
Journal Articles
Journal: Blood
Blood (2016) 128 (22): 4927.
Published: 2016
... in non‐Hodgkin lymphomas (NHL) and especially chronic lymphocytic leukemia (CLL); until now only few cases have been described in patients affected by multiple myeloma (MM) and other plasma cell disorders. The introduction of new drugs, in particular immunomodulatory drugs (IMiDs), could increase...
Journal Articles
Journal: Blood
Blood (2017) 130 (Supplement 1): 1268.
Published: 2017
.../refractory (R/R) mantle cell lymphoma (MCL). The relationship between acalabrutinib plasma exposure and safety was evaluated in patients with B-cell malignancies that included R/R MCL, chronic lymphocytic leukemia, follicular lymphoma, diffuse large B-cell lymphoma, multiple myeloma and Waldenström...
Journal Articles
Journal: Blood
Blood (2016) 128 (22): 4615.
Published: 2016
... + memory T cell infusion at three dose levels. Median age was 59 years (range, 29 to 70 years). Diagnoses included acute myeloid leukemia (n= 8), non-Hodgkin lymphoma (n= 3), chronic lymphocytic leukemia (n= 1), chronic myeloid leukemia (n=1), multiple myeloma (n=1), and acute lymphoblastic leukemia (n=1...
Journal Articles
Journal: Blood
Blood (2021) 138 (Supplement 1): 566.
Published: 2021
..., a new significant advancement in hematological malignancies, is currently approved for use in multiple myeloma (MM), acute lymphoblastic leukemia (ALL), diffuse large B cell lymphoma (DLBCL), mantle cell lymphoma (MCL) and follicular lymphoma (FL). Enrollment of Blacks in clinical trials that supported...
Journal Articles
Journal: Blood
Blood (2019) 134 (Supplement_1): 4442.
Published: 2019
... trial (NCT01029366 / B lymphoma, leukemia / CD19 target / n=20) showed 3 cases (15%) of pneumonia, 1 case each of C Diff, Pseudomonas and salmonella (5%) infections. A Phase 2 trial (NCT02030834, B NHL, CD19 target, n=63) treated patients showed 34% patients experienced infection which included sepsis...
Journal Articles
Journal: Blood
Blood (2008) 112 (11): 2756.
Published: 2008
... for antibody therapeutics for the treatment of various hematological malignancies, including multiple myeloma as well as non-Hodgkin’s lymphoma, chronic lymphocytic leukemia, acute lymphocytic leukemia, acute myeloid leukemia, and chronic myeloid leukemia. CD38 is a type II transmembrane glycoprotein...
Journal Articles
Journal: Blood
Blood (2018) 132 (Supplement 1): 5914.
Published: 2018
... underlie differences in cognitive functioning among patients treated for hematological malignancies. Methods. The sample comprised participants treated for lymphoma or multiple myeloma who were participating in a feasibility study of a computerized cognitive training program. Prior to the intervention...
Journal Articles
Journal: Blood
Blood (2021) 138 (Supplement 1): 4318.
Published: 2021
... inhibit MYC and BCL2 are currently under investigation; however, there is no established standard-of-care for these highly aggressive lymphomas. Menin is a scaffold protein that is essential for cancers driven by oncogenic MLL-fusions, such as in acute leukemias. At present, the role of menin in DLBCL...
Journal Articles
Journal: Blood
Blood (2014) 124 (21): 4131.
Published: 2014
.... Results: A total of 109 patients (median age 61 years [range 21–89 years]) were enrolled; 55 females and 54 males, 36 hematological malignancies (multiple myeloma [n=15], malignant lymphoma [n=10], chronic myeloid leukemia [n=10], and acute lymphoblastic leukemia [n=1]), 70 solid tumors (breast [n=14...